| Weight | 811.878 g/mol |
|---|---|
| Formula | C42H53NO15 |
| Hydrogen Acceptors | 16 |
| Hydrogen Donors | 4 |
| Aromatic Rings | 2 |
| Rotatable Bonds | 9 |
Aclacinomycin A
Aclarubicin · NSC-208734 · Aclaplastin
57576-44-0, 64520-15-6, 77448-81-8
"What do you need help with?"
LabBot
- Sigma-Aldrich - Search for Aclacinomycin A
- Fisher Scientific - Search for Aclacinomycin A
- TCI - Search for Aclacinomycin A
- Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients (Human Molecular Genetics, 2001)
- Antagonistic Effect of Aclarubicin on the Cytotoxicity of Etoposide and 4-(9-Acridinylamino)methanesulfon-m-anisidide in Human Small Cell Lung Cancer Cell Lines and on Topoisomerase II-mediated DNA Cleavage (Cancer Research, 1990)
- Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle (Biochemical Pharmacology, 1996)
- Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark. (Leukemia, 1991)
- Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia : a pilot study (Leukemia, 1995)
- Low-Dose Cytarabine and Aclarubicin in Combination With Granulocyte Colony-Stimulating Factor (CAG Regimen) for Previously Treated Patients With Relapsed or Primary Resistant Acute Myelogenous Leukemia (AML) and Previously Untreated Elderly Patients With AML, Secondary AML, and Refractory Anemia With Excess Blasts in Transformation (International Journal of Hematology, 2000)
-
Predict GHS Hazards for Any Chemical in silico.
Including Acute Oral Tox, Skin Sensitization, Eye Irritation, Aquatic Tox, & more. - Aclarubicin
- NSC-208734
- Aclaplastin
- Aclacin
- NSC208734
- MA144A1
- MA-144A1
- NSC 208734
- MA 144A1
-
SMILESCCC1(CC(C2=C(C1C(=O)OC)C=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4O)OC5CC(C(C(O5)C)OC6CC(C(C(O6)C)OC7CCC(=O)C(O7)C)O)N(C)C)O
-
InChIKeyUSZYSDMBJDPRIF-UHFFFAOYSA-N
- Pubchem - Aclacinomycin A
- Wikipedia - Aclarubicin
Aclarubicin (INN) or aclacinomycin A is an anthracycline drug that is used in the treatment of cancer. Soil bacteria Streptomyces galilaeus can produce aclarubicin. It can induce histone eviction from chromatin upon intercalation.
Suppliers
Most-cited Publications
Areas of Application
Safety
Trends
Alternate Names
External Links
Similar Compounds
Spinosyn-A
(131929-60-7)
10 alternate names
1 safety hazard
3 suppliers
Rifamycin SV
(15105-92-7, 6998-60-3)
10 alternate names
3 suppliers
oleandomycin
(3922-90-5)
10 alternate names
3 suppliers
oleandomycin
(3922-90-5)
10 alternate names
3 suppliers
oleandomycin
(3922-90-5)
10 alternate names
3 suppliers
oleandomycin
(3922-90-5)
10 alternate names
3 suppliers
oleandomycin
(3922-90-5)
10 alternate names
3 suppliers
oleandomycin
(3922-90-5)
10 alternate names
3 suppliers
Lymecycline
(992-21-2)
10 alternate names
3 suppliers
Lymecycline
(992-21-2)
10 alternate names
3 suppliers
Ciclolysal
(992-21-2)
10 alternate names
3 suppliers
Coxistac
(53003-10-4)
10 alternate names
1 safety hazard
3 suppliers
53003-10-4
(53003-10-4)
10 alternate names
1 safety hazard
3 suppliers
salinomycin
(53003-10-4)
10 alternate names
1 safety hazard
3 suppliers
salinomycin
(53003-10-4)
10 alternate names
1 safety hazard
3 suppliers
salinomycin
(53003-10-4)
10 alternate names
1 safety hazard
3 suppliers
salinomycin
(53003-10-4)
10 alternate names
1 safety hazard
3 suppliers
salinomycin
(53003-10-4)
10 alternate names
1 safety hazard
3 suppliers
salinomycin
(53003-10-4)
10 alternate names
1 safety hazard
3 suppliers
salinomycin
(53003-10-4)
10 alternate names
1 safety hazard
3 suppliers
Ivermectin B1a
(70161-11-4, 70288-86-7, 71827-03-7)
10 alternate names
3 suppliers
IVERMECTIN
(70288-86-7)
10 alternate names
3 suppliers
IVERMECTIN
(70288-86-7)
10 alternate names
3 suppliers
IVERMECTIN
(70288-86-7)
10 alternate names
3 suppliers
IVERMECTIN
(70288-86-7)
10 alternate names
3 suppliers
IVERMECTIN
(70288-86-7)
10 alternate names
3 suppliers
IVERMECTIN
(70288-86-7)
10 alternate names
3 suppliers
IVERMECTIN
(70288-86-7)
10 alternate names
3 suppliers
IVERMECTIN
(70288-86-7)
10 alternate names
3 suppliers
Vulcamycin
(1476-53-5)
10 alternate names
3 suppliers
70288-86-7
(70288-86-7)
10 alternate names
3 suppliers
Capsanthin
(465-42-9)
10 alternate names
3 suppliers
monensin
(17090-79-8)
10 alternate names
2 safety hazards
3 suppliers
monensin
(17090-79-8)
10 alternate names
2 safety hazards
3 suppliers
monensin
(17090-79-8)
10 alternate names
2 safety hazards
3 suppliers
monensin
(17090-79-8)
10 alternate names
2 safety hazards
3 suppliers
monensin
(17090-79-8)
10 alternate names
2 safety hazards
3 suppliers
Novobiocin (Sodium)
(1476-53-5)
10 alternate names
3 suppliers
Canthaxanthin
(514-78-3)
10 alternate names
3 suppliers
Albamycin
(1476-53-5)
10 alternate names
3 suppliers
Vulcamycin
(1476-53-5)
10 alternate names
3 suppliers
ROLITETRACYCLINE
(751-97-3)
10 alternate names
3 suppliers
LUTEOSKYRIN
(21884-44-6)
10 alternate names
3 suppliers
thapsigargin
(67526-95-8)
10 alternate names
3 suppliers
hyperforin
(11079-53-1)
10 alternate names
3 suppliers
hiperforina
(11079-53-1)
10 alternate names
3 suppliers
CARMINIC ACID
(1390-65-4, 1260-17-9)
10 alternate names
3 suppliers
Carmine
(1390-65-4, 1260-17-9, 1343-78-8)
10 alternate names
3 suppliers
CAS Directory
